Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid
- Development stage
- Unknown
- Lead developer
- Nationwide Children's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This investigational nutritional intervention is a specific combination of long-chain polyunsaturated fatty acids (LCPUFAs), including the omega-6 fatty acid gamma-linolenic acid (GLA) and the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Developed for evaluation in clinical trials led by Sarah Keim at Nationwide Children's Hospital, the supplement is being studied for its potential to modulate biological signatures and improve behavioral symptoms in children aged 2 to 6 with autism spectrum disorder (ASD). LCPUFAs are essential for neuronal membrane integrity and serve as precursors to signaling molecules that regulate neuroinflammation and neurotransmission. The study specifically monitors changes in pro-inflammatory cytokines such as IL-1β, IL-2, and IFNγ to correlate biological changes with clinical improvements in ASD symptoms.
- Other names
- LCPUFA Oil SupplementOmega 3-6 oilOmega3-6 oilOmega-3-6 oilGLA+EPA+DHA
02
Targets
PPAR (PPAR family)COXFFAR (Free fatty acid receptor family)
Beyond the preview
Go deeper on gamma-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gamma-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid.